Nanologica has now approved a number of normal-sized batches from the large-scale production of the company's silica for preparative chromatography, NLAB Saga®.

Scaling up to large-scale production of silica at the contract manufacturer Sterling Pharma Solutions has been fraught with several challenges such as loss of material, which has previously been communicated. Although a couple of challenges remain, the company has now for the first time completed several large production batches in a row, which means that a stock of certain products has been built up.
 
“It is very pleasing that our large-scale silica production facility is now delivering significantly larger volumes than before. This does not mean that production is optimized. There is still a lot of work to be done, for example, to further increase yield in certain steps and to improve the production economy. However, having a stock is very important. It means that we are now confident in being able to deliver, which means that we can drive sales harder”, CEO Andreas Bhagwani comments.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments
Newsletter: The Production of NLAB Saga® Stabilizes

© Modular Finance, source Nordic Press Releases